BRPI0412127A - método de tratar pelo menos um sintoma ou condição, uso de um composto, composição farmacêutica, e uso da mesma - Google Patents
método de tratar pelo menos um sintoma ou condição, uso de um composto, composição farmacêutica, e uso da mesmaInfo
- Publication number
- BRPI0412127A BRPI0412127A BRPI0412127-9A BRPI0412127A BRPI0412127A BR PI0412127 A BRPI0412127 A BR PI0412127A BR PI0412127 A BRPI0412127 A BR PI0412127A BR PI0412127 A BRPI0412127 A BR PI0412127A
- Authority
- BR
- Brazil
- Prior art keywords
- pharmaceutical composition
- treating
- pharmaceutically acceptable
- symptom
- compound
- Prior art date
Links
- 208000024891 symptom Diseases 0.000 title abstract 5
- 238000000034 method Methods 0.000 title abstract 3
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 3
- 150000001875 compounds Chemical class 0.000 title abstract 2
- 208000019901 Anxiety disease Diseases 0.000 abstract 2
- 208000020925 Bipolar disease Diseases 0.000 abstract 2
- 230000036506 anxiety Effects 0.000 abstract 2
- 150000003839 salts Chemical class 0.000 abstract 2
- 206010001497 Agitation Diseases 0.000 abstract 1
- 208000028698 Cognitive impairment Diseases 0.000 abstract 1
- 206010012289 Dementia Diseases 0.000 abstract 1
- 208000030814 Eating disease Diseases 0.000 abstract 1
- 208000019454 Feeding and Eating disease Diseases 0.000 abstract 1
- 206010020400 Hostility Diseases 0.000 abstract 1
- 206010026749 Mania Diseases 0.000 abstract 1
- 208000019022 Mood disease Diseases 0.000 abstract 1
- 208000028017 Psychotic disease Diseases 0.000 abstract 1
- 238000013019 agitation Methods 0.000 abstract 1
- 208000010877 cognitive disease Diseases 0.000 abstract 1
- 239000003085 diluting agent Substances 0.000 abstract 1
- 235000014632 disordered eating Nutrition 0.000 abstract 1
- 239000003937 drug carrier Substances 0.000 abstract 1
- 230000036651 mood Effects 0.000 abstract 1
- 208000015122 neurodegenerative disease Diseases 0.000 abstract 1
- 201000000980 schizophrenia Diseases 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/554—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one sulfur as ring hetero atoms, e.g. clothiapine, diltiazem
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Psychiatry (AREA)
- Epidemiology (AREA)
- Pain & Pain Management (AREA)
- Hospice & Palliative Care (AREA)
- Psychology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US48436503P | 2003-07-02 | 2003-07-02 | |
| PCT/GB2004/002783 WO2005002586A1 (en) | 2003-07-02 | 2004-06-28 | Metabolite of quetiapine |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BRPI0412127A true BRPI0412127A (pt) | 2006-08-15 |
Family
ID=33563981
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BRPI0412127-9A BRPI0412127A (pt) | 2003-07-02 | 2004-06-28 | método de tratar pelo menos um sintoma ou condição, uso de um composto, composição farmacêutica, e uso da mesma |
Country Status (20)
| Country | Link |
|---|---|
| US (1) | US20050026900A1 (https=) |
| EP (1) | EP1644005B1 (https=) |
| JP (1) | JP2007516193A (https=) |
| KR (1) | KR20060082037A (https=) |
| CN (1) | CN1816339B (https=) |
| AR (1) | AR045004A1 (https=) |
| AT (1) | ATE477803T1 (https=) |
| AU (1) | AU2004253334A1 (https=) |
| BR (1) | BRPI0412127A (https=) |
| CA (1) | CA2531284A1 (https=) |
| DE (1) | DE602004028739D1 (https=) |
| ES (1) | ES2349091T3 (https=) |
| IL (1) | IL172616A0 (https=) |
| IS (1) | IS8283A (https=) |
| MX (1) | MXPA05013869A (https=) |
| NO (1) | NO20060556L (https=) |
| RU (1) | RU2005141060A (https=) |
| TW (1) | TW200509944A (https=) |
| UY (1) | UY28400A1 (https=) |
| WO (1) | WO2005002586A1 (https=) |
Families Citing this family (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL164155A0 (en) * | 2002-03-20 | 2005-12-18 | Teva Pharma | Crystalline forms of quetiapine hemifumarate |
| WO2008021463A2 (en) * | 2006-08-15 | 2008-02-21 | Acadia Pharmaceuticals, Inc. | Amino substituted diaryl[a,d]cycloheptene analogs as muscarinic agonists and methods of treatment of neuropsychiatric disorders |
| PT1696931E (pt) | 2003-12-22 | 2009-06-12 | Acadia Pharm Inc | Análogos diaril[a,d]ciclo-hepteno substituídos com amino utilizados como agonistas muscarínicos e métodos de tratamento de perturbações neuropsiquiátricas |
| US20060081361A1 (en) * | 2004-09-13 | 2006-04-20 | Gabbey Lawrence W | Oil cooler with integral filter |
| JP2008526839A (ja) * | 2005-01-07 | 2008-07-24 | アストラゼネカ・アクチエボラーグ | １１−ピペラジン−１−イルジベンゾ［ｂ，ｆ］［１，４］チアゼピン又はその薬学的に許容される塩の新規な使用及び経口医薬組成物への新規な使用 |
| AU2006231497A1 (en) * | 2005-04-04 | 2006-10-12 | Acadia Pharmaceuticals Inc. | Use of N-desmethylclozapine and related compounds as dopamine stabilizing agents |
| US7687622B2 (en) * | 2005-04-14 | 2010-03-30 | Teva Pharmaceutical Industries, Ltd | Process for preparing quetiapine fumarate |
| WO2007004234A1 (en) * | 2005-07-04 | 2007-01-11 | Usv Limited | A PROCESS FOR THE PREPARATION OF 2-[2-(4-DIBENZO[b,f] [L,4] THIAZEPIN-11-yl-1- PIPERAZINYL)ETHOXY] ETHANOL FUMARATE |
| WO2008079848A1 (en) * | 2006-12-20 | 2008-07-03 | Astrazeneca Ab (Se/Se) | Compounds and uses thereof |
| WO2007062337A2 (en) * | 2005-11-18 | 2007-05-31 | Astrazeneca Ab | Crystalline forms |
| WO2007062339A2 (en) * | 2005-11-18 | 2007-05-31 | Astrazeneca Ab | Liquid formulations |
| WO2008116144A1 (en) * | 2007-03-22 | 2008-09-25 | Astrazeneca Ab | Methods of treating mood disorders |
| JP2009516705A (ja) * | 2005-11-18 | 2009-04-23 | アストラゼネカ・アクチエボラーグ | 塩の形態 |
| US8389510B2 (en) | 2005-11-18 | 2013-03-05 | Astrazeneca Ab | Crystalline forms |
| WO2007062338A2 (en) * | 2005-11-18 | 2007-05-31 | Astrazeneca Ab | Solid formulations |
| WO2008118141A2 (en) * | 2006-10-17 | 2008-10-02 | Acadia Pharmaceuticals Inc. | Use of cannabinoid modulating compounds in combination with other therapeutic compounds for adjunctive therapy |
| JP2010531292A (ja) * | 2006-12-20 | 2010-09-24 | アストラゼネカ・アクチエボラーグ | 化合物及びその使用 |
| EP2120563A4 (en) * | 2006-12-20 | 2011-04-27 | Astrazeneca Ab | CONNECTIONS AND ITS USES |
| US8715699B2 (en) | 2009-12-31 | 2014-05-06 | Kempharm, Inc. | Amino acid conjugates of quetiapine, process for making and using the same |
| WO2011112657A1 (en) | 2010-03-11 | 2011-09-15 | Kempharm, Inc. | Fatty acid conjugates of quetiapine, process for making and using the same |
| CN102552128B (zh) * | 2012-02-28 | 2013-09-18 | 陆荣政 | 一种富马酸喹硫平注射液及其制备方法 |
| US9993486B1 (en) | 2017-06-19 | 2018-06-12 | Tlc Therapeutics, Llc | Oral quetiapine suspension formulations with extended shelf life and enhanced bioavailability |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NL140242B (nl) * | 1963-03-01 | 1973-11-15 | Wander Ag Dr A | Werkwijze voor het bereiden van op de 11-plaats door een basische groep gesubstitueerde dibenz (b.f.)(1.4) oxazepinen. |
| GB1192812A (en) * | 1966-05-20 | 1970-05-20 | American Cyanamid Co | 2-Chloro-11-(1-Piperazinyl)Dibenz[b,f]-[1,4]Oxazepine, Non-Toxic Acid Addition Salts thereof, and Therapeutic Compositions containing said Oxazepine or Salts |
| US3539573A (en) * | 1967-03-22 | 1970-11-10 | Jean Schmutz | 11-basic substituted dibenzodiazepines and dibenzothiazepines |
| US3966949A (en) * | 1973-10-12 | 1976-06-29 | Richardson-Merrell Inc. | Pharmaceutical compositions and preparing same |
| GB8607684D0 (en) * | 1986-03-27 | 1986-04-30 | Ici America Inc | Thiazepine compounds |
| US5750566A (en) * | 1994-08-12 | 1998-05-12 | Eli Lilly And Company | Synthetic excitatory amino acids |
| WO2000010572A1 (en) * | 1998-08-18 | 2000-03-02 | Sepracor Inc. | Use of hydroxyrisperidone for the manufacture of a medicament for the treatment and prevention of psychoses, emesis and symptoms of withdrawal from alcohol and nicotine |
| JP2006515628A (ja) * | 2003-01-23 | 2006-06-01 | アカディア ファーマシューティカルズ，インコーポレーテッド | ヒト神経精神疾患を処置するためのｎ−デスメチルクロザピンの使用 |
-
2004
- 2004-06-28 KR KR1020057025264A patent/KR20060082037A/ko not_active Withdrawn
- 2004-06-28 CA CA002531284A patent/CA2531284A1/en not_active Abandoned
- 2004-06-28 ES ES04743131T patent/ES2349091T3/es not_active Expired - Lifetime
- 2004-06-28 WO PCT/GB2004/002783 patent/WO2005002586A1/en not_active Ceased
- 2004-06-28 JP JP2006518324A patent/JP2007516193A/ja not_active Ceased
- 2004-06-28 BR BRPI0412127-9A patent/BRPI0412127A/pt not_active IP Right Cessation
- 2004-06-28 AT AT04743131T patent/ATE477803T1/de not_active IP Right Cessation
- 2004-06-28 DE DE602004028739T patent/DE602004028739D1/de not_active Expired - Lifetime
- 2004-06-28 EP EP04743131A patent/EP1644005B1/en not_active Expired - Lifetime
- 2004-06-28 AU AU2004253334A patent/AU2004253334A1/en not_active Abandoned
- 2004-06-28 CN CN2004800188710A patent/CN1816339B/zh not_active Expired - Fee Related
- 2004-06-28 RU RU2005141060/15A patent/RU2005141060A/ru not_active Application Discontinuation
- 2004-06-28 MX MXPA05013869A patent/MXPA05013869A/es not_active Application Discontinuation
- 2004-07-01 US US10/883,024 patent/US20050026900A1/en not_active Abandoned
- 2004-07-02 UY UY28400A patent/UY28400A1/es not_active Application Discontinuation
- 2004-07-02 AR ARP040102345A patent/AR045004A1/es not_active Application Discontinuation
- 2004-07-02 TW TW093120058A patent/TW200509944A/zh unknown
-
2005
- 2005-12-15 IL IL172616A patent/IL172616A0/en unknown
-
2006
- 2006-02-01 IS IS8283A patent/IS8283A/is unknown
- 2006-02-02 NO NO20060556A patent/NO20060556L/no not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| US20050026900A1 (en) | 2005-02-03 |
| CA2531284A1 (en) | 2005-01-13 |
| NO20060556L (no) | 2006-04-03 |
| WO2005002586A8 (en) | 2006-02-09 |
| IL172616A0 (en) | 2006-04-10 |
| DE602004028739D1 (de) | 2010-09-30 |
| RU2005141060A (ru) | 2006-07-27 |
| MXPA05013869A (es) | 2006-02-28 |
| JP2007516193A (ja) | 2007-06-21 |
| IS8283A (is) | 2006-02-01 |
| KR20060082037A (ko) | 2006-07-14 |
| AU2004253334A1 (en) | 2005-01-13 |
| WO2005002586A1 (en) | 2005-01-13 |
| TW200509944A (en) | 2005-03-16 |
| ATE477803T1 (de) | 2010-09-15 |
| EP1644005A1 (en) | 2006-04-12 |
| UY28400A1 (es) | 2005-01-31 |
| ES2349091T3 (es) | 2010-12-27 |
| AR045004A1 (es) | 2005-10-12 |
| CN1816339B (zh) | 2010-12-15 |
| CN1816339A (zh) | 2006-08-09 |
| EP1644005B1 (en) | 2010-08-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BRPI0412127A (pt) | método de tratar pelo menos um sintoma ou condição, uso de um composto, composição farmacêutica, e uso da mesma | |
| DE69529670D1 (de) | Oxazolidinon derivate und diese enthaltende pharmazeutische zusammensetzungen | |
| PT1404324E (pt) | Formas de dosagem administradas oralmente de pró-fármacos análogas de gaba tendo toxicidade reduzida | |
| CY1111047T1 (el) | Θεραπεια οφθαλμικων νεοαγγειακων διαταραχων οπως κηλιδωδους εκφυλισμου, αγγειοειδων γραμμωσεων, ραγοειδιτιδας και οιδηματος της ωχρης κηλιδας | |
| CY1111206T1 (el) | Βενζοθειοφαινια υποκατεστημενα με πιπεραζινη για την αγωγη διανοητικων διαταραχων | |
| BR0206434A (pt) | Composto, composição, e, métodos de tratamento ou de prevenção da recidiva de depressão, de um distúrbio de ansiedade, de um distúrbio da alimentação e de um distúrbio de incontinência urinária em um paciente | |
| BR0113666A (pt) | Inibidores da protease peptidomimética | |
| BR9408378A (pt) | Composto sal farmaceuticamente aceitável composição farmacêutica e processos para o tratamento de um paciente que sofreu um derrame e que sofre de uma condição de perda progressiva de função de sistema nervoso central e para melhorar os efeitos colaterais causados em um paciente por tratamento antineoplástico de doença que produz danos oxidativos | |
| BR0210267A (pt) | Composição farmacêutica sólida, processo para preparar a mesma, conjunto para o tratamento de obesidade, utilização da composição, processo de tratamento de obesidade e inibidor de lìpases | |
| BR0309486A (pt) | Composto ou um seu sal farmaceuticamente aceitável, composição farmacêutica, e, método para o tratamento de uma condição associada com um excesso de taquicininas | |
| GB9305623D0 (en) | Therapeutic agents | |
| BRPI0412262A (pt) | derivados de azepina como agentes farmacêuticos | |
| DE60206454D1 (de) | Difluormethylen aromatische Ether und ihre Verwendung als Inhibitoren des Glycin-Typ-1-Transporters | |
| BR0308796A (pt) | Derivados de benzofurano | |
| BRPI0313286A2 (pt) | Composição e atividade antiviral de derivados de piperazina azaindoloxoacético substituìda | |
| BRPI0512958A (pt) | antagonistas de nk1 | |
| TWI340639B (en) | Pharmaceutical composition for treating luts, other than urinary incontinence, associated with oab and/or bph | |
| EE200100478A (et) | Vahend artriitilise haiguse raviks | |
| ATE295183T1 (de) | Mittel zur linderung von juckreiz, enthaltend pgd2- antagonisten | |
| EP1666064A4 (en) | MEANS FOR THE TREATMENT OF DISEASES RELATED TO IMMUNOGLOBULIN GEN TRANSLATION | |
| BR9910185A (pt) | Uso de um composto, e, processo para o tratamento de um paciente que sofre de, ou em risco de, uma doença micobacteriana | |
| TW200507854A (en) | Metabolite | |
| DE68925173D1 (de) | 4-Methyl und 4-Ethyl substituierte Pyrrolidin-2-one | |
| ATE431147T1 (de) | Mittel zur behandlung des integrationsdysfunktionssyndroms | |
| KR910018028A (ko) | 15- 데히드록시-16-옥소프로스타글란딘 화합물에 의한 생화학적 치료 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE AS 5A, 6A, 7A E 8A ANUIDADES. |
|
| B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2159 DE 22/05/2012. |